KYMR - Kymera Therapeutics, Inc.
About Kymera Therapeutics, Inc. (https://www.kymeratx.com)
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Nello Mainolfi | Co-Founder, President, Chief Executive Officer & Director | 1979 | $1,226,750 USD |
| Jared A. Gollob | Chief Medical Officer | 1965 | $806,344 USD |
| Bruce N. Jacobs | Chief Financial Officer | – | $795,250 USD |
| Jeremy G. Chadwick | Chief Operating Officer | 1963 | $719,400 USD |
| Noah Goodman | Chief Business Officer | 1987 | $597,289 USD |
| Brian R. Adams | Chief Legal Officer & Corporate Secretary | 1974 | $540,095 USD |
| Bruce L. Booth DPHIL | Co-Founder & Independent Chairman | 1974 | $70,000 USD |
| Brian Albarran | SVP of Corporate Strategy | – | – |
| Juliet Williams | Head of Research | – | – |
| Justine E. Koenigsberg | Vice President of Investor Relations | – | – |
| Karen Weisbach | Head of People & Culture | – | – |
| Neil Graham MBBS | Chief Development Officer | 1959 | – |